Hans van Houte, Chief Financial Officer at Nurix Therapeutics, Inc. (NRIX), sold 20,000 shares at $25.22 ($504K) on 2024-08-26, disclosed to the SEC on 2024-08-26.
Scheduled sale ($504k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| NRIX | SELL | 2026-05-05 | $233K | — | Filing → |
| NRIX | SELL | 2026-04-30 | $40K | — | Filing → |
| NRIX | SELL | 2026-01-30 | $122K | — | Filing → |